Madrigal (MDGL) Q4 2025 earnings review
Rezdiffra Hits $1B Run-Rate; Pipeline Explodes
Madrigal capped a transformative 2025 with $321M in Q4 net sales, pushing the annualized run-rate well past $1 billion. Patient adoption is accelerating, crossing 36,250 (up from 11,800 a year ago). While the commercial launch is executing near-flawlessly, the company aggressively pivoted from a single-product story to a platform play, licensing six siRNA programs and a DGAT-2 inhibitor. However, the costs of this expansion and commercial support pushed Operating Expenses to $381M, keeping profitability on the horizon rather than in hand.
๐ Bull Case
Rezdiffra is tracking as one of the best specialty launches in history. Revenue tripled YoY ($103M to $321M), and sequential growth remains double-digit (+12% QoQ) even as the base expands.
Madrigal effectively addressed the 'one-trick pony' risk. By adding siRNA programs, an oral GLP-1 (MGL-2086), and Ervogastat, they are building a defensive moat around Rezdiffra before competitors arrive.
๐ป Bear Case
Management previously flagged a step-up in GTN discounts to the 'high 30% range' for 2026 to secure broad coverage. This pricing pressure means volume growth must significantly outpace revenue growth to maintain momentum.
Despite nearly $1B in revenue, the company is not profitable. Operating expenses ($1.26B FY25) exceeded revenue ($958M). High R&D spend ($116M in Q4) and commercial costs signal continued burn.
โ๏ธ Verdict: ๐ข๐ข
Strong Buy. Madrigal is executing a textbook blockbuster launch. The rapid patient uptake validates the clinical profile, and the aggressive pipeline expansion secures long-term relevance. Financials are messy due to BD deals and launch costs, but top-line velocity is undeniable.
Key Themes
Patient Uptake Accelerating
Patient adoption shows no signs of saturation. The company added ~6,750 patients in Q4, accelerating from the ~6,500 added in Q3. With >36,250 patients on therapy, they have penetrated over 11% of the initial 315,000 target F2/F3 market in under two years.
Spending Surge
Operating leverage remains elusive as the company doubles down on growth. SG&A surged to $240M in Q4 (up from $141M YoY), and R&D spiked to $116M (up from $25M YoY), driven partly by upfront payments for business development. While necessary for a platform play, this pushes the breakeven point further out.
From Product to Platform
Q4 marked a strategic pivot. By licensing global rights to six pre-clinical siRNA programs and the oral DGAT-2 inhibitor Ervogastat, Madrigal is moving beyond THR-ฮฒ agonism. This prepares them for a future of combination therapies (Rezdiffra + siRNA or Rezdiffra + GLP-1) to combat liver fat and fibrosis simultaneously.
Pricing Pressure (Gross-to-Net)
While not explicitly quantified in the release text, the 'step up' in GTN discounts remains a critical watch item. In Q3, management guided for 'high 30% range' GTN in 2026. This implies that for every $100 of product shipped, Madrigal will only retain ~$60-65, a significant headwind compared to the 'minimal' impact seen early in the launch.
European Launch Slow Roll
Rezdiffra launched in Germany in September 2025. While it's the first approved MASH therapy in the EU, management has previously tempered expectations, calling it a '2026 story.' The revenue contribution from outside the U.S. remains negligible in current numbers but represents the next leg of volume growth.
Patent Fortress
The company secured an Orange Book listing for the Rezdiffra patent covering the weight-threshold dosing regimen, extending protection into 2045. This 20-year runway is exceptionally long for a launched commercial asset, justifying the heavy investment in pipeline combination assets.
Other KPIs
Stable. Up from $931M at end of 2024, primarily due to the new credit facility ($350M term loan) and financing, offsetting the operational cash burn. The $500M credit facility provides a buffer, but burn remains high.
Accelerating. Up 354% YoY ($25.6M in 24Q4). The sharp increase is driven by upfront payments for the siRNA and other licensing deals. This masks the underlying run-rate but shows aggressive capital deployment.
Accelerating. A massive leap from $180M in the partial year of 2024. The drug is on the cusp of 'blockbuster' status (>$1B sales) in its first full year, a rare feat in specialty pharma.
Guidance
Accelerating. Management expects 'another year of robust net sales growth' driven by broad first-line access. No specific numeric range was provided, but the trend line implies crossing $1.5B is likely.
Stable/On-Track. The oral GLP-1/orforglipron derivative is scheduled to enter clinical trials in Q2 2026. This is a critical milestone for the combination strategy.
New. Following the licensing deal, IND-enabling work kicks off this year, adding to the early-stage R&D burden.
Key Questions
Gross-to-Net Precision
You previously guided to a 'high 30% range' GTN impact for 2026. With 2026 payer contracts now active, is this range holding, or have you seen deeper discounting requirements to secure the 'broad first-line access' mentioned?
European Ramp
Germany launched in September. Can you quantify the early uptake or at least the number of prescribers engaged? When do you expect material revenue contribution from the EU?
Combination Trial Design
With the oral GLP-1 entering the clinic in Q2, are you planning immediate combination studies with Rezdiffra, or will you need to clear monotherapy safety hurdles first? What is the fastest path to a combo label?